Skip to main content
TipRanks
Go Ultimate75% OFF

Scancell Holdings (SCLP) AI Stock Analysis

26 Followers
GB:SCLP

Scancell Holdings

(LSE:SCLP)

Select Model
Rating:49Neutral
Price Target:GBX 79.00â–²(0.00% Upside)
Action:reiterated
Date:10/22/26

The overall score is heavily constrained by the company's precarious financial position, with a near-insolvent balance sheet and a cash runway of less than two years. While the clinical and regulatory progress for the lead asset iSCIB1+ is exceptional and represents a significant value driver, the immediate risk of dilutive financing and the deeply bearish technical trend weigh heavily on the near-term outlook. The company's future hinges entirely on successful financing or partnership deals to bridge the gap to its 2029 Phase III readout.

Positive Factors
Phase III Regulatory ReadinessFDA IND clearance removes a major regulatory hurdle and indicates that iSCIB1+ has an agreed development framework for its registrational study. Acceptance of a surrogate endpoint may also support an accelerated approval route, improving the program’s commercial pathway if efficacy is confirmed.
Negative Factors
Persistent Losses and No RevenueThe company currently lacks recurring commercial revenue and continues to report substantial operating and net losses. This weak earnings base means future investment depends on external funding, partnered receipts or eventual product success rather than internally generated operating cash.

Scancell Holdings (SCLP) vs. iShares MSCI United Kingdom ETF (EWC)

-50%0%50%100%150%200%GB:SCLP-16.84%EWC+8.99%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
GBP 95.77M
Dividend Yield
―
Average Volume (3M)
216.62K
Price to Earnings (P/E)
-4.5
Beta (1Y)
-0.05
Revenue Growth
-100.00%
EPS Growth
-30.39%
Country
UK
Employees
55
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Scancell Holdings Business Overview & Revenue Model

Company Description

Scancell Holdings plc is a clinical-stage biopharmaceutical firm focused on discovering and developing innovative vaccine and antibody treatments. Its mission is to address significant unmet medical needs in both cancer and infectious diseases. The c...

Scancell Holdings Earnings Call Summary

Earnings Call Date:Jan 29, 2026(Q2-2026)|% Change Since:-40.93%|Next Earnings Date:Jan 30, 2024
Earnings Call SentimentPositive

The call conveyed strong clinical and regulatory progress—most notably the FDA IND clearance, compelling PFS data (74% at 16 months with a 24% delta), validated manufacturing and delivery, and multiple pipeline and partnered value drivers (including up to $630M in Genmab milestones). The primary negatives are financial (no revenue, interim net loss, and a cash runway into H2 2026) and the long, blinded Phase III timeline to a registrational readout in H2 2029 which necessitates near-term financing or milestone receipts. On balance, the positive clinical/regulatory milestones and clear commercial pathway outweigh the funding and timing headwinds.

Positive Updates

Strong Efficacy Signal for iSCIB1+ (PFS)
iSCIB1+ demonstrated progression-free survival (PFS) of 74% at 16 months in Phase II data; reported a 24% delta versus historic/real-world benchmarks (comparison with ipilimumab+nivolumab median PFS ~11.5 months). Company also reported a ~16% improvement for prior SCIB1 on overall survival versus the comparator in their dataset, and noted similarity in order of magnitude to published Moderna 5‑year follow-up data.

Negative Updates

No Revenues Reported in Period
There were no revenues in the interim period; revenue upside depends on future partnered milestones (Genmab) and commercial success.

Company Guidance

Management guided that iSCIB1+—which showed 74% PFS at 16 months (a ~24 percentage‑point delta versus historic ipi/nivo data with median PFS ≈11.5 months) from a Phase II translational dataset of ~140 patients—will move to a registrational Phase III two‑arm study of ~230 patients per arm (~460 total) with an adaptive design, IND cleared by the FDA, a surrogate primary endpoint (enabling accelerated approval), plans to pursue Fast Track and a Breakthrough designation (decision timeline ~2–3 months) and a target readout/commercialization window in H2 2029; financially, H1 (6 months to 31 Oct 2025) R&D spend was $6.2m, admin costs £2.7m, operating loss £8.9m, net loss £5.7m, cash £8.6m (including a £3.0m R&D tax credit) giving runway into H2 2026, while management pursues partnering/financing (including up to $630m of potential Genmab milestones), expects Modi‑1 data in H1, anticipates further Genmab/SC129 milestones this year, and notes patent protection to 2041 plus scalable manufacturing and a PharmaJet needle‑free delivery partnership.

Scancell Holdings Financial Statement Overview

Summary

Financial health is critically weak. The company is pre-revenue with persistent, deep operating losses and a negative equity balance sheet. Cash burn, while slightly improved, remains substantial, creating a high risk of requiring dilutive financing. The only minor positive is the high gross margin on sporadic revenue, which is entirely overshadowed by the severe cash drain and insolvent balance sheet.

Income Statement

8Very Negative

Balance Sheet

5Very Negative

Cash Flow

15Very Negative
Financial statement breakdown
BreakdownTTMApr 2026Apr 2025Apr 2024Oct 2023Apr 2022
Income Statement
Total Revenue004.71M05.27M0
Gross Profit-672.00K-672.00K3.59M-966.00K4.75M-740.00K
EBITDA-13.69M-16.75M-12.71M-7.06M-12.19M-3.75M
Net Income-17.90M-17.90M-12.27M-5.86M-11.94M-2.06M
Balance Sheet
Total Assets10.36M10.36M23.09M23.58M30.27M49.06M
Cash, Cash Equivalents and Short-Term Investments5.32M5.32M16.89M14.82M19.92M28.73M
Total Debt17.08M17.08M16.27M19.87M21.13M18.92M
Total Liabilities29.77M29.77M26.93M27.08M36.50M29.57M
Stockholders Equity-19.41M-19.41M-3.83M-3.50M-6.23M18.11M
Cash Flow
Free Cash Flow-10.56M-10.56M-6.12M-15.84M-8.34M-8.55M
Operating Cash Flow-10.56M-10.56M-6.11M-15.66M-8.14M-7.80M
Investing Cash Flow356.00K356.00K-1.54M178.00K81.00K-741.00K
Financing Cash Flow-1.35M-1.35M9.73M10.39M-746.00K46.08M

Scancell Holdings Technical Analysis

Technical Analysis SentimentNegative
Last Price79.00

Price Trends

50DMA90.39Negative
100DMA99.35Negative
200DMA129.83Negative

Market Momentum

MACD-3.35Positive
RSI29.70Positive
STOCH22.22Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:SCLP, the sentiment is Negative. The current price of 79.00 is below the 20-day moving average (MA) of 83.77, below the 50-day MA of 90.39, and below the 200-day MA of 129.83, indicating a bearish trend. The MACD of -3.35 indicates Positive momentum. The RSI at 29.70 is Positive, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:SCLP.

Scancell Holdings Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:SCLP against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
GB:4BBGB:4BB52NeutralGBP 100.70M-4.53-316.73%―-56.10%-16.77%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
GB:SCLPGB:SCLP49NeutralGBP 96.98M-4.51128.87%―-100.00%-30.39%
GB:SARGB:SAR47NeutralGBP 23.75M-6.04-188.01%――28.78%
GB:POLBGB:POLB42NeutralGBP 48.10M-7.88-71.28%――31.58%
GB:OBIGB:OBI40UnderperformGBP 57.20M-2.40-9999.00%―26.99%4.36%
GB:ARECGB:AREC33UnderperformGBP 34.43M143.003.75%―――

* Healthcare Sector Average

Performance Comparison

0%50%100%150%GB:SCLPGB:SARGB:4BBGB:POLBGB:ARECGB:OBIDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:SCLP and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:SCLPScancell Holdings79.00-15.50-16.40%
GB:SARSareum Holdings14.501.5011.54%
GB:4BB4basebio UK Societas525.00-187.50-26.32%
GB:POLBPoolbeg Pharma Ltd.6.152.6073.24%
GB:ARECArecor Therapeutics PLC71.50-2.50-3.38%
GB:OBIOndine Biomedical, Inc.8.25-3.00-26.67%

Scancell Holdings Corporate Events

Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsShareholder MeetingsStock Split

Scancell clears share consolidation as it readies AIM trading and deal push

Positive
Oct 20, 2026

Scancell Holdings has confirmed that all resolutions at its latest general meeting were approved, paving the way for a share consolidation in which every 10 existing ordinary shares of 0.1 pence will be combined into one new ordinary share of 1 pence...

Financial DisclosuresShareholder MeetingsStock Split

Scancell Issues Shares Ahead of Consolidation and Publishes 2026 Annual Report

Neutral
Oct 15, 2026

Scancell Holdings has issued seven new ordinary shares to chief executive Dr Phil L’Huillier to ensure its share capital is exactly divisible by ten ahead of a planned share consolidation on a 10-for-1 basis. The new shares, which represent a negligi...

Business Operations and StrategyDelistings and Listing ChangesFinancial DisclosuresM&A TransactionsPrivate Placements and FinancingProduct-Related Announcements

Scancell Bolsters Cancer Immunotherapy Push With Nasdaq Move and $75m Funding

Positive
Oct 9, 2026

Scancell reported progress across its immunotherapy pipeline, led by iSCIB1+, which has U.S. fast track status and regulatory clearance in the UK for a Phase 3 trial in unresectable Stage IIIB or IV melanoma, with around 550 patients to be enrolled a...

Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and FinancingShareholder MeetingsStock Split

Scancell Sets Vote on Neuphoria Merger and 10-for-1 Share Consolidation

Positive
Oct 2, 2026

Scancell Holdings has released a circular and called a general meeting for 20 October 2026 to seek shareholder approval for its planned merger with Neuphoria Therapeutics and associated financing for a registrational Phase 3 study of melanoma therapy...

Business Operations and StrategyDelistings and Listing ChangesM&A TransactionsPrivate Placements and Financing

Scancell Secures Up to US$25m BlackRock Debt to Drive iSCIB1+ Phase 3

Positive
Sep 24, 2026

Scancell Holdings has secured a loan facility of up to US$25 million from funds managed by BlackRock, adding a structured layer of debt financing to support its planned Phase 3 development of lead melanoma candidate iSCIB1+ and complementing the prop...

Business Operations and StrategyM&A Transactions

Scancell to Highlight Late-Stage Cancer Immunotherapy and U.S. Deal Plans at Wainwright Conference

Positive
Sep 3, 2026

Scancell Holdings will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, with management hosting in-person investor meetings and providing a webcasted presentation accessible via the company’s website for...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2026